Is ribociclib available in China? How much does it cost?

Ribociclib, English nameRibociclib, trade name Kisqali, is a kinase inhibitor that has attracted much attention in the field of cancer treatment in recent years. It specifically targets and inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), which play key roles in cell division. By blocking the activity of these kinases, ribociclib prevents cancer cells from entering the S phase from the G1 phase, effectively inhibiting the division and proliferation of cancer cells.

Ribociclib is mainly used to treat postmenopausal patients with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. It is used in combination with aromatase inhibitors as initial endocrine therapy in such patients, significantly improving therapeutic efficacy. Clinical studies have shown that compared with placebo, ribociclib combination treatment can reduce the risk of disease progression or death and significantly extend patients' progression-free survival.

In terms of usage and dosage, ribociclib is administered orally. The recommended dose is600 mg once a day. It should be taken for 21 consecutive days and then stopped for 7 days. A 28-day treatment cycle is considered. This method of administration helps ensure the continuity of drug efficacy while reducing the occurrence of adverse reactions.

However, ribociclib may also cause some side effects during use, such as neutropenia, nausea, fatigue, diarrhea, etc. Therefore, it is necessary to closely monitor the patient's response during use and adjust the treatment plan in a timely manner according to the situation.

Ribocini has now been launched in the domestic market, priced at about 8,000 yuan. It is reported that the original drug of Ribociclib is also sold overseas. Two specifications are available in the European market, and the packaging of 200mg*21 tablets is about 22,000 yuan per box. In addition, the original drug Ribociclib is also available in the Indian market, and the price is more affordable, about 3,000 yuan per box. Whether sold in Europe or India, they are all original versions of ribociclib, but the sales locations are different.

Overall, ribociclib, as a breakthrough anti-cancer drug, provides a new treatment option for patients with advanced breast cancer, resulting in longer survival and better quality of life.